NYMC Faculty Publications
Rasburicase vs. Allopurinol: Mortality in Hematological Malignancies Post Anti-Hyperuricemic Therapy - Real-World Study
Author Type(s)
Student
DOI
10.1007/s00520-025-10090-y
Journal Title
Supportive Care in Cancer
Document Type
Article
Publication Date
12-1-2025
Department
Pediatrics
Keywords
Hematological malignancy, Hyperuricemia (HUA), Liquid tumor, Propensity score (PS), Real-world (RW), Retrospective, Tumor lysis syndrome (TLS)
Disciplines
Medicine and Health Sciences
Abstract
Purpose: This retrospective, real-world (RW) study utilizing propensity score matching investigated tumor lysis syndrome (TLS)-related mortalities following anti-hyperuricemic (HU) monotherapy (allopurinol vs. rasburicase) in hematological malignancies. The study aim was to determine if a significant difference exists in the proportion of TLS-associated mortalities in hematological malignancy patients who received either rasburicase or allopurinol. Methods: Following random selection of patient cases of rasburicase or allopurinol monotherapy, 141 in each group were PS-matched for TLS risk using 11 predictive covariates. Results: Rasburicase-treated patients had significantly lower TLS-associated mortality (2.1% (n = 3) vs. 7.1% (n = 10) (p = 0.047)). Conclusions: Following successful PS matching of TLS-risk factors, this study suggests rasburicase statistically significantly reduces TLS-associated mortalities compared to allopurinol.
Recommended Citation
Cairo, M., Gallagher, J., Barnes, Y., Drea, E., Clark, C., & Carroll, S. (2025). Rasburicase vs. Allopurinol: Mortality in Hematological Malignancies Post Anti-Hyperuricemic Therapy - Real-World Study. Supportive Care in Cancer, 33 (12). https://doi.org/10.1007/s00520-025-10090-y
